- Organigram (TSX:OGI) announced its financial results for its Q2 of fiscal 2025, showing off notable growth across various metrics
- Gross revenue increased by 79 per cent to $102.8 million, up from $57.4 million in the same period last year
- Net revenue rose by 74 per cent to $65.6 million, compared to $37.6 million in the prior year period
- Organigram stock (TSX:OGI) last traded at C$1.64
Organigram (TSX:OGI) announced its financial results for its Q2 of fiscal 2025, showing off notable growth across various metrics.
Financial highlights
- Gross revenue: Increased by 79 per cent to $102.8 million, up from $57.4 million in the same period last year.
- Net revenue: Rose by 74 per cent to $65.6 million, compared to $37.6 million in the prior year period.
- International revenue: Surged by 177 per cent to $6.1 million, up from $2.2 million year-over-year.
- Adjusted gross margin: Improved to $21.9 million or 33 per cent, from $11.6 million or 31 per cent in the same period last year.
- Adjusted EBITDA: Jumped to $4.9 million, a significant turnaround from $(1.0) million in the previous year.
- Cash position: The company maintains a robust cash position of approximately $83.4 million with negligible debt.
Operational achievements
- Market leadership: Organigram continues to hold the #1 market share position in Canada, leading in categories such as vapes, pre-rolls, milled flower, hash, and pure CBD gummies. The company is also ranked #3 in edibles and dried flower.
- Motif integration: The integration of Motif is now expected to exceed initial estimates, providing approximately $15 million in annual cost synergies, up from the original estimate of $10 million.
- Acquisition of Collective Project Ltd.: This acquisition marks Organigram’s entry into the burgeoning U.S. and Canadian beverage markets, with current distribution in 10 states and six provinces.
International expansion
- Organigram achieved $6.1 million in international sales during Q2 Fiscal 2025 and anticipates further growth in the second half of the fiscal year. The company has established supply agreements with partners in Germany, the U.K., and Australia, and is exploring additional global partnership opportunities.
Organigram’s CEO, Beena Goldenberg expressed optimism about the company’s trajectory, highlighting the strong financial performance and strategic initiatives that position the company for sustained growth in the competitive cannabis market.
“We are unlocking meaningful global growth potential — from increasing sales into key international markets like Germany, to our entrance into the U.S. hemp-derived beverage space,” she said in a media release. “We expect this momentum to continue as we further strengthen our leadership in Canada and head into the seasonally stronger back half of the year.”
About Organigram
Organigram is a licensed Canadian producer of cannabis, cannabis-derived products and cannabis infused edibles. Its brand portfolio includes Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer.
Organigram stock (TSX:OGI) last traded at C$1.64 and was up 3.14 per cent last week, but down 31.67 per cent since this time last year.
Join the discussion: Find out what everybody’s saying about this cannabis stock in Canada on the Organigram Holdings Inc. Bullboard and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
